Immunol Allergy Clin North Am. 2024 May;44(2):397-406. doi: 10.1016/j.iac.2024.01.010. Epub 2024 Feb 10.
ABSTRACT
Data for pharmacologic treatments for non-eosinophilic esophagitis (EoE) eosinophilic gastrointestinal diseases (EGIDs) are limited. Nevertheless, because of the increasing understanding of EGID pathogenesis, a number of medications are used to treat EGIDs, though all are currently off-label. Initial therapy generally starts with corticosteroids, and “topical” delivery is preferred over systemic due to long-term side effects. A number of other small molecules could potentially be used, ranging from allergy medications to immunosuppressants. Biologics are also being used and investigated for EGIDs and represent promising targeted therapies. Multiple therapeutic targets have also been identified, many of which overlap with EoE targets.
PMID:38575232 | DOI:10.1016/j.iac.2024.01.010
